Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Phase II Randomized Study With R-DHAP +/- Bortezomib as Induction Therapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Patients Eligible to Transplantation. BR-DHAP Versus R-DHAP. (FIL_VERAL12)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01805557
Recruitment Status : Active, not recruiting
First Posted : March 6, 2013
Last Update Posted : July 7, 2020
Sponsor:
Collaborators:
Janssen Pharmaceutica
Janssen-Cilag Ltd.
Centro di Riferimento per l'Epidemiologia e la Prev. Oncologica Piemonte
Information provided by (Responsible Party):
Fondazione Italiana Linfomi ONLUS

Brief Summary:
The probability to achieve CR with R-chemotherapy in patients failing a rituximab containing first line regimen is quite low, in particular in cases with non GCB profile. The bioCORAL trial suggest that ABC subset have a dismal outcome whichever the induction treatment. Thus it can be argued the addition of new molecule to the RDHAP regimen could be of value. Bortezomib appears the best candidate in this setting as ABC subtypes constitutively express NFkb, which is the target of bortezomib itself. Data from the literature suggest an encouraging activity of R-chemo+ bortezomib in non GCB-derived DLBCL, although in small series. Thus, the addition of bortezomib is here justified by the need to circumvent constitutional resistance to chemotherapy. Published experience of the association between bortezomib and cytarabine are also encouraging with acceptable cumulative toxicity.

Condition or disease Intervention/treatment Phase
Diffuse Large B-cell Lymphoma Refractory Diffuse Large B-cell Lymphoma Recurrent Drug: R-DHAP Drug: BR-DHAP Phase 2 Phase 3

Detailed Description:

This is a prospective, multicenter, two-arm randomized phase II screening trial34 in young patients (18-65 years) affected by relapsed/refractory Diffuse Large B-cell Lymphoma (DLBCL) at diagnosis, eligible to high-dose therapy.

Aim of the study is to to assess whether the addition of Bortezomib to R-DHAP is more promising than standard R-DHAP, as induction therapy before high dose chemotherapy with ASCT with respect to response and safety. Patients will be randomized at first relapse between: a) the standard salvage therapy Rituximab in association to DHAP every 28 days (R-DHAP) for 4 cycles and b) Bortezomib in association to the same regimen (BR-DHAP). In both arms the induction therapy is followed by autologous stem cell transplantation or, if indicated, by allogeneic stem cell transplant.

A patient is considered evaluable if it is possible to assess response by PET after 4 cycle or, if a patient withdraws from the study for PD, before completion of study treatment.

After providing written informed consent, patients will be evaluated for eligibility during a 21-day screening period. If they continue to meet eligibility criteria, they will be randomized to receive the first dose of BR-DHAP or R-DHAP .

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 108 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase II Randomized Study With R-DHAP +/- Bortezomib as Induction Therapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Patients Eligible to Transplantation. BR-DHAP Versus R-DHAP.
Actual Study Start Date : February 4, 2013
Actual Primary Completion Date : March 12, 2019
Estimated Study Completion Date : November 21, 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lymphoma
Drug Information available for: Bortezomib

Arm Intervention/treatment
Active Comparator: R-DHAP
R-DHAP x 2, restaging, mobilization and harvest of peripheral stem cell + R-DHAP x 2, restaging with PET evaluation
Drug: R-DHAP
  • Rituximab 375 mg/sqm iv day 0 or 1
  • Cisplatin 100 mg/sqm iv day 1 in 6-hours infusion
  • Cytarabine 2000 mg/sqm in 3-hours infusion iv day 2 and day 3
  • Dexamethasone 40 mg day 1-4
  • Pegfilgrastim 6 mg sc monodose 24 hours after the end of chemotherapy or G-CSF from day 5 till stem cell harvest during mobilization's course (II o III cycle R-DHAP)
  • Rituximab 375 mg/sqm iv 24 hours before apheresis as purging in vivo during second courses of therapy

Experimental: BR-DHAP
Bortezomib + R-DHAP x 2, restaging, mobilization and harvest of peripheral stem cell + Bortezomib + R-DHAP x 2, restaging with PET evaluation
Drug: R-DHAP
  • Rituximab 375 mg/sqm iv day 0 or 1
  • Cisplatin 100 mg/sqm iv day 1 in 6-hours infusion
  • Cytarabine 2000 mg/sqm in 3-hours infusion iv day 2 and day 3
  • Dexamethasone 40 mg day 1-4
  • Pegfilgrastim 6 mg sc monodose 24 hours after the end of chemotherapy or G-CSF from day 5 till stem cell harvest during mobilization's course (II o III cycle R-DHAP)
  • Rituximab 375 mg/sqm iv 24 hours before apheresis as purging in vivo during second courses of therapy

Drug: BR-DHAP
  • Rituximab 375 mg/sqm iv day 0 or 1
  • Bortezomib SC 1.5 mg/sqm day 1, day 4
  • Cisplatin 100 mg/sqm iv day 1 in 6-hours infusion
  • Cytarabine 2000 mg/sqm in 3-hours infusion iv day 2 and day 3
  • Dexamethasone 40 mg day 1-4
  • Pegfilgrastim 6 mg sc monodose 24 hours after the end of chemotherapy or G-CSF from day 5 till stem cell harvest during mobilization's course (II o III cycle R-DHAP)
  • Rituximab 375 mg/sqm iv 24 hours before apheresis as purging in vivo during second courses of therapy Chemotherapy R-DHAP and BR-DHAP will be repeated every 28 days.




Primary Outcome Measures :
  1. Complete Response (CR) Rate [ Time Frame: At the end of the induction phase (6 months) ]
    Proportion of CR according to the Cheson 2007 response criteria, evaluated by PET scan


Secondary Outcome Measures :
  1. Overall Response Rate (ORR) [ Time Frame: At the end of the induction phase (6 months) ]
    ORR at the end of the induction treatment is defined as Complete Response (CR) or Partial Response according to the Cheson 2007 response criteria, evaluated by PET scan

  2. Overall Survival (OS) [ Time Frame: 36 months ]
    OS will be defined as the time between the date of randomization and the date of death from any cause

  3. Number of Patients With Treatment-Related Adverse Events (AEs)/Serious Adverse Events (SAEs) as a Measure of Safety [ Time Frame: 12 months ]
    Incidence of grade 3 or higher Toxicity measured by CTCAE v.4 during therapy

  4. Mobilizing potential [ Time Frame: 6 months ]
    Amount of CD34+ stem cell collected/Kg

  5. Number of Patients completing ASCT [ Time Frame: 12 months ]
    Proportion of randomized patients successfully completing ASCT



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Age 18-65
  2. Relapsed/refractory disease after receiving one line of standard chemoimmunotherapy (R-CHOP, GA-CHOP, R-CHOP like)
  3. Diffuse Large B-cell Lymphoma at relapse. Patient has to be re-biopsied prior to study entry. If this is harmful for the patient, the patient can be enrolled if archivial tumor sample and block from first diagnosis are available.
  4. No prior Bortezomib therapy
  5. Measurable and/or evaluable disease
  6. Any Ann Arbor stage and IPI group at relapse
  7. Performance status < 2 according to ECOG scale unless due to lymphoma
  8. No Central Nervous System (CNS) disease (meningeal and/or brain involvement by lymphoma)
  9. Adequate hematological counts: ANC > 1.5 x 109/L, Hgb > 9 g/dl (transfusion independent), Platelet count > 75 x 109/L (transfusion independent), with the exception of cytopenia due to lymphoma bone marrow involvement
  10. HIV negativity, HCV negativity, HBV negativity or patients with HBcAb +, HBsAg -, HBs Ab+/- with HBV-DNA negativity (in these patients Lamivudine prophylaxis is mandatory)
  11. Normal liver function (ALP, AST, ALT, GGT, conjugated bilirubin total < 2 x ULN) if not related to lymphoma
  12. Normal kidney function (creatinine clearance > 45 ml/min)
  13. Cardiac ejection fraction > 50% (MUGA scan or echocardiography)
  14. Normal lung function
  15. Absence of active opportunistic infections
  16. Non peripheral neuropathy or active neurological non neoplastic disease of CNS
  17. Non major surgical intervention prior 3 months to randomization if not due to lymphoma and/or no other disease life-threatening that can compromise chemotherapy treatment
  18. Disease free of prior malignancies other than lymphoma for > 3 years with exception of currently treated squamous cell and basal cell carcinoma of the skin or carcinoma in situ of the cervix or breast
  19. Life expectancy > 6 months
  20. No psychiatric illness that precludes understanding concepts of the trial or signing informed consent
  21. Written informed consent
  22. Women must be:

    • postmenopausal for at least 1 year (must not have had a natural menses for at least 12 months)
    • surgically sterile (have had a hysterectomy or bilateral oophorectomy, tubal ligation, or otherwise be incapable of pregnancy),
    • abstinent (at the discretion of the investigator/per local regulations), or
    • if sexually active, be practicing a highly effective method of birth control (eg, prescription oral contraceptives, contraceptive injections, contraceptive patch, intrauterine device, double-barrier method (eg, condoms, diaphragm, or cervical cap, with spermicidal foam, cream, or gel, male partner sterilization) as local regulations permit, before entry, and must agree to continue to use the same method of contraception throughout the study. They must also be prepared to continue birth control measures for at least 12 months after terminating treatment.
  23. Women of childbearing potential must have a negative serum or urine beta-human chorionic gonadotropin (beta-hCG) pregnancy test at screening
  24. Men must agree to use an acceptable method of contraception (for themselves or female partners as listed above) for the duration of the study. Men must agree to use a double barrier method of birth control and to not donate sperm during the study and for 3 months after receiving the last dose of study drug.

Exclusion criteria:

  1. Diagnosis of Lymphoblastic Lymphoma, Burkitt Lymphoma, Non Hodgkin Lymphoma CD20 negative, Mantle Cell Lymphoma, Follicular Lymphoma g I-II-IIIa-IIIb, Primary Mediastinal Lymphoma
  2. Age > 65 years
  3. Patients ineligible to high-dose chemotherapy
  4. Performance status > 2 according to ECOG scale if not due to lymphoma
  5. Patient has known or suspected hypersensitivity or intolerance to Rituximab
  6. Patient has received an experimental drug or used an experimental medical device within 4 weeks before the planned start of treatment. Concurrent participation in non-treatment studies is allowed, if it will not interfere with participation in this study.
  7. CNS disease (meningeal and/or brain involvement by lymphoma)
  8. History of clinically relevant liver or renal insufficiency; significant cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, rheumatologic, hematologic, psychiatric, or metabolic disturbances
  9. Uncontrolled diabetes (if receiving antidiabetic agents, subjects must be on a stable dose for at least 3 months before first dose of study drug
  10. Uncontrolled or severe cardiovascular disease including myocardial infarction within six months of enrollment, New York Heart Association (NYHA) Class III or IV heart failure, uncontrolled angina, clinically significant pericardial disease, or cardiac amyloidosis
  11. Cardiac ejection fraction < 50% (MUGA scan or echocardiography)
  12. Creatinine clearance < 45 ml/min
  13. Presence of major neurological disorders
  14. HIV positivity, HCV positivity, HBV positivity with the exception of patients with HBcAb +, HbsAg -, HBs Ab+/- with HBV-DNA negative
  15. Active opportunistic infection
  16. Major surgical intervention prior 3 months to randomization if not due to lymphoma and/or other disease life-threatening that can compromise chemotherapy treatment
  17. Prior malignancies other than lymphoma in the last 3 years with exception of currently treated squamous cell and basal cell carcinoma of the skin or carcinoma in situ of the cervix or breast
  18. Life expectancy < 6 months
  19. Any other coexisting medical or psychological condition that would preclude participation in the study or compromise ability to give informed consent.
  20. If female, the patient is pregnant or breast-feeding.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01805557


Locations
Show Show 24 study locations
Sponsors and Collaborators
Fondazione Italiana Linfomi ONLUS
Janssen Pharmaceutica
Janssen-Cilag Ltd.
Centro di Riferimento per l'Epidemiologia e la Prev. Oncologica Piemonte
Investigators
Layout table for investigator information
Study Director: Umberto Vitolo, MD SC Ematologia 2-AO Città della Salute e della Sienza-Molinette
Layout table for additonal information
Responsible Party: Fondazione Italiana Linfomi ONLUS
ClinicalTrials.gov Identifier: NCT01805557    
Other Study ID Numbers: FIL_VERAL12
First Posted: March 6, 2013    Key Record Dates
Last Update Posted: July 7, 2020
Last Verified: November 2019
Keywords provided by Fondazione Italiana Linfomi ONLUS:
Diffuse Large B-cell Lymphoma (DLBCL)
Bortezomib
Additional relevant MeSH terms:
Layout table for MeSH terms
Lymphoma
Lymphoma, B-Cell
Lymphoma, Large B-Cell, Diffuse
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Lymphoma, Non-Hodgkin